Final-Program-ATS-2023-AP.vp

SUNDAY • MAY 21

103

12:10 Data Tools for State and Local Estimates for Chronic Obstructive Pulmonary Disease - part 2 K. Watson, PhD, Atlanta, GA 12:20 Think. Test. Treat TB. Starting the Conversation N. DeLuca, PhD, MA, Atlanta, GA 12:35 Directly Observed Therapy Updates and Recommendations J.M.C. Mangan, PhD, ATLANTA, GA 12:50 Panel Discussion and Audience Questions C. Winston, PhD, Atlanta, GA

12:25 Programs and Funding Opportunities in Sleep and Respiratory Health Disparities: Clinical and Health Services Research L. Aviles-Santa, MD, MPH, Bethesda, MD 12:35 Exposure to Violence, Epigenetic Variation, and Asthma in Puerto Rican Children J.C. Celedon, MD, DrPH, ATSF, Pittsburgh, PA 12:50 Panel Discussion R. Das, PhD, Bethesda, MD

CENTERS FOR DISEASE CONTROL OUTSIDE ORGANIZATION SESSION

DIVISION OF LUNG DISEASES, NHLBI/NIH OUTSIDE ORGANIZATION SESSION

L2

UPDATES FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION: TOOLS FOR CLINICIANS 12:00 PM - 1:00 PM Walter E. Washington Convention Center Room 152 A-B (Street Level) Target Audience Clinicians, academics, and public health practitioners interested in chronic and acute lung disease Objectives At the conclusion of this session, the participant will be able to: • Identify local geographic areas where chronic pulmonary disease burden is highest and better understand demographic differences within their state. • improve communication and education with patients at risk for acute and chronic disease by using evidence-based, culturally- and linguistically-appropriate resources to explain tuberculosis risk, recommended testing, and treatment options. • Incorporate updated recommendations and describe the current evidence, operational challenges, and need to address patient preferences for the use of directly observed therapy during treatment and management of medication adherence. New tools from the U.S. Centers for Disease Control presented will help clinical providers and researchers to identify local populations among whom tuberculosis and chronic pulmonary disease risk is highest, to better understand demographic differences in risk within their local area, to communicate effectively with patients, and to use an updated approach to monitoring medication adherence. These tools and resources will enhance health screenings and patient outcomes. Chairing: C. Winston, PhD, Atlanta, GA 12:00 Data Tools for State and Local Estimates for Chronic Obstructive Pulmonary Disease - part 1 S.A. Carlson, PhD, MPH, Atlanta, GA

L3

RECENT CLINICAL AND OMICS FINDINGS IN PATIENTS WITH PULMONARY HYPERTENSION FROM THE NHLBI PVDOMICS PROGRAM 12:00 PM - 1:00 PM Walter E. Washington Convention Center Room 202 A (Level 2) Target Audience Healthcare providers, researchers, and trainees with an interest in pulmonary hypertension Objectives At the conclusion of this session, the participant will be able to: • learn about new genomic findings including rare variant analysis and mRNA transcriptomic profiles in the peripheral blood of patients with pulmonary hypertension • learn about metabolic changes that precede a diagnosis of PAH in scleroderma patients. • learn about the effect of pollution on pulmonary vascular disease, right ventricular function and HRQL in the PVDOMICS cohort. This session will cover new research discoveries stemming from the NHLBI “Redefining Pulmonary Hypertension through Pulmonary Vascular Disease Phenomics (PVDOMICS)” program that seeks to better understand clinical and molecular aspects of pulmonary hypertension (PH), a complex disease with high mortality. This national observational clinical study co-sponsored by NHLBI and the Pulmonary Hypertension Association is performing extensive phenotyping in a large cohort of 1200 participants, which includes the prospective collection and analysis of biomarker, genetic, genomic, and phenotypic clinical data from subjects with PH for the purpose of identifying subpopulations and intermediate outcome measures. Chairing: L. Xiao, MD, PhD, Bethesda, MD N.S. Hill, MD, Boston, MA

ATS 2023 • Washington, DC